Rethinking neoadjuvant chemotherapy for breast cancer
This BMJ analysis notes that neoadjuvant chemotherapy may not be beneficial to patients as increased pathological response of primary tumour does not translate into a survival benefit. It suggests that the widespread use of neoadjuvant chemotherapy should be reduced.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Health | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy